Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.61 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 6/20 | 0.45 |
| ▸ | CTSD | P07339 | 4/20 | 0.45 |
| ▸ | ECE1 | P42892 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384747 | 1.00 | PDCD1LG2 (0.61) | PDCD1LG2CD274BACE1CTSDECE1 | |
| SCHEMBL29630384 | 0.93 | PDCD1LG2 (0.53) | PDCD1LG2CD274BACE1CTSDECE1 | |
| SCHEMBL30390448 | 0.91 | CD274 (0.52) | PDCD1LG2CD274BACE1CTSDECE1 | |
| SCHEMBL29434624 | 0.91 | PDCD1LG2 (0.50) | PDCD1LG2CD274MMETGFBR1 | |
| SCHEMBL29994005 | 0.89 | PDCD1LG2 (0.51) | PDCD1LG2CD274BACE1CTSDKISS1R | |
| SCHEMBL31182877 | 0.89 | CD274 (0.60) | PDCD1LG2CD274BACE1CTSDECE1 | |
| SCHEMBL30011715 | 0.88 | PDCD1LG2 (0.52) | PDCD1LG2CD274BACE1CTSDECE1 | |
| SCHEMBL16582447 | 0.87 | CD274 (0.79) | PDCD1LG2CD274ECE1MMEKISS1R | |
| SCHEMBL29679898 | 0.86 | PDCD1LG2 (0.48) | PDCD1LG2CD274BACE1CTSDECE1 | |
| SCHEMBL30737580 | 0.86 | BACE1 (0.50) | PDCD1LG2CD274BACE1CTSDECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2024-08-22 | — | — | US | disclosed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4065169-A1 | COMBINATION THERAPY | ADC Therapeutics SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PDCD1LG2 326/4885CD274 1121/4885BACE1 4530/4885 |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PDCD1LG2 326/4885CD274 1121/4885BACE1 4530/4885 |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PDCD1LG2 118/4885CD274 395/4885BACE1 3829/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | PDCD1LG2 150/4885CD274 490/4885BACE1 3665/4885 |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PDCD1LG2 326/4885CD274 1121/4885BACE1 4530/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PDCD1LG2 326/4885CD274 1121/4885BACE1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.